Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference
Cabaletta Bio (Nasdaq: CABA), a clinical-stage biotechnology firm, announced that CEO Steven Nichtberger, M.D., will participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on October 3, 2022, at 4:00 p.m. ET in New York. The event will be webcast live, and a replay will be available for 30 days on their website. Cabaletta Bio specializes in engineered T cell therapies aimed at treating autoimmune diseases, with a pipeline focusing on conditions like pemphigus vulgaris and myasthenia gravis.
- None.
- None.
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on Monday, October 3, 2022 at 4:00 p.m. ET in New York, NY.
A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays of the presentation will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform, in combination with Cabaletta Bio’s proprietary technology, has advanced a growing pipeline that currently includes potential treatments for patients with mucosal pemphigus vulgaris, MuSK-associated myasthenia gravis, PLA2R-associated membranous nephropathy, mucocutaneous pemphigus vulgaris and hemophilia A with FVIII alloantibodies. Cabaletta Bio’s headquarters are located in Philadelphia, PA. For more information, visit www.cabalettabio.com and follow us on LinkedIn.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
Sarah McCabe
Stern Investor Relations, Inc.
sarah.mccabe@sternir.com
FAQ
When is Cabaletta Bio's presentation at the Chardan Conference?
Who will represent Cabaletta Bio at the conference?
Where can I watch the Cabaletta Bio presentation?
What is the focus of Cabaletta Bio's research?
What autoimmune diseases does Cabaletta Bio target?
